MEL1 (MDS1/EVI1-like gene 1/PRDM16), which was identified as a gene near the chromosomal breakpoint in t(1;3)(p36;q21)-positive human acute myeloid leukemia cells, belongs to the PRDI-BF1-RIZ1 homologous (PR) domain (PRDM) family of transcription repressors. The short form of MEL1 (MEL1S), which lacks the PRdomain at the N-terminus, is the main form expressed in t(1;3)(p36;q21)-positive acute myeloid leukemia cells. The overexpression of MEL1S blocks granulocyte colonystimulating factor (G-CSF)-induced myeloid differentiation in interleukin-3-dependent murine myeloid L-G3 cells. In this study, we show that treatment with the histone deacetylase inhibitor trichostatin A abolished the blockade of myeloid differentiation in L-G3 cells overexpressing MEL1S. The expression of MEL1S containing mutated CtBP-interacting motif (CIM) in L-G3 cells still blocked the myeloid differentiation induced by G-CSF. We found that the small ubiquitin-related modifier (SUMO) motif (SM) at lysine 568 (VKAE) adjacent to the CIM was necessary to obtain the maximum transcriptional repressor activity of MEL1S. L-G3 cells expressing MEL1S, and bearing mutated CIM and SM differentiated into granulocytes in response to G-CSF; this indicated that both the SUMO modification at lysine 568 and CtBP binding were required for MEL1S-mediated transcriptional repression and blockade of differentiation, which might be relevant for the process of leukemogenesis.
Introduction
Acute myeloid leukemia with reciprocal translocation t(1;3)(p36;q21) is frequently characterized by trilineage dysplasia, particularly dysmegakaryocytopoiesis, and a poor prognosis (Moir et al., 1984; Bloomfield et al., 1985; Welborn et al., 1987) . These clinical features are very similar to those of the 3q21q26 syndrome, which is characterized by a high expression of the ecotropic viral integration site-1 (EVI1) gene . EVI1 (also called PR domain member 3 or PRDM3) is a zinc-finger transcription factor and belongs to the PRDI-BF1-RIZ1 homologous (PR) domain family (Morishita, 2007) . We previously identified the MDS1/ EVI1-like gene 1 (MEL1) as a member of the EVI1 gene family and also as a PR domain family member (PRDM16); this gene is located near the chromosomal breakpoint at chromosome 1p36 of t(1;3)(p36;q21) (Mochizuki et al., 2000; Shimizu et al., 2000) . PRdomain deficient forms of EVI1 and MEL1 (MEL1S) are upregulated in both types of leukemia (Mochizuki et al., 2000; Nishikata et al., 2003) . We discovered that the overexpression of MEL1S in murine interleukin-3 (IL-3)-dependent myeloid L-G3 cells blocked the granulocytic differentiation induced by granulocyte colony-stimulating factor (G-CSF) (Nishikata et al., 2003) . Using the GAL4 DNA-binding domain (DBD) fused to MEL1 and MEL1S, we also identified that both MEL1 and MEL1S function as transcriptional repressors (Nishikata et al., 2003) .
EVI1 and MEL1 also belong to a family of transcription factors with C-terminal-binding protein (CtBP)-interacting motif (CIM) (Shimahara et al., 2010) . EVI1 has two CIMs, PFDLT (aa 553-559) and PLDLS (aa 584-590), and the repressor and cell-transforming functions of EVI1 are mediated by its CtBPbinding activity (Izutsu et al., 2001) . Moreover, MEL1/ PRDM16 also has two CIMs, and PLDLS (aa 616-620), and was reported to directly interact with a CtBP co-repressor complex on the promoter of white fat-specific genes .
CtBP was originally identified as a transcriptional corepressor of the adenoviral E1A protein (Schaeper et al., 1995) . In addition, among transcription factors containing zinc-finger repeats, BKLF, ZEB1, ZEB2 (Shimahara et al., 2010) and ZNF217 (Quinlan et al., 2006) have been reported to have CIM. The CtBP co-repressor complex contains a number of epigenetic regulatory factors that mediate coordinated histone modification by deacetylation and methylation of histone H3 at lysine 9 and demethylation of histone H3 at lysine 4 (Chinnadurai, 2007) . CtBP also recruits the small ubiquitin-related modifier (SUMO) and conjugates the E2 enzyme UBC9 and a SUMO E3 ligase (HPC2) (Kagey et al., 2003) . Therefore, it is possible that sumoylation might also be involved in CtBP-mediated transcriptional regulation.
In this study, we investigated whether the transcriptional repressor activity of MEL1 could mediate the blockade of the granulocytic differentiation of L-G3 cells induced by G-CSF. The L-G3 cells treated with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) overcame blockade of the G-CSF-induced differentiation by MEL1S expression. Here, the transcriptional repression by MEL1S is reported to be mediated by sumoylation and its interaction with CtBP. MEL1S interacted with the E2-conjugating enzyme UBC9, which led to sumoylation, and interacted with the transcriptional co-repressor CtBP. Site-directed mutagenesis and deletion analysis identified lysine 568 as a sumoylation site in MEL1S. Mutations of both the sumoylation site and the CIMs in MEL1S completely abrogated the repressor activity and released the MEL1S-induced differentiation block in L-G3 cells. Therefore, the transcriptional repressor activity of MEL1S is likely one of the important determinants in the development of leukemia.
Results
Combining G-CSF with TSA treatment overcomes the blockade of G-CSF-induced differentiation in murine L-G3 cells induced by MEL1S expression We previously reported that the short form of MEL1 (MEL1S), a transcription factor that is specifically expressed in acute myeloid leukemia with the t(1;3) translocation, could block G-CSF-induced myeloid differentiation of L-G3, an IL-3-dependent myeloid leukemia cell line (Nishikata et al., 2003) . Because MEL1S works as a transcriptional repressor in hematopoietic cells, including L-G3 cells ( Supplementary  Figure 1) , we initially investigated whether treatment of L-G3 cells with the HDAC inhibitor TSA prevents the blockade of G-CSF-induced differentiation by MEL1S expression. A series of L-G3 cell lines, consisting of parental cells or cells transfected with a Mock-vector (L-G3/Mock) or a MEL1S expression vector (L-G3/ MEL1S), were cultured with IL-3, G-CSF or G-CSF with TSA for 6 days, and their cell growth, morphology and expression of myeloperoxidase (Mpo) and lactoferrin (Lf) (Friedman et al., 1991) , both of which are markers of granulocyte differentiation, were determined. At 6 days after treatment with G-CSF, most of the parental L-G3 cells and L-G3/Mock cells exhibited reduced cell growth, increased cell death, differentiation to granulocytes with multi-lobulated nuclei and expression of Mpo and Lf; however, the majority of L-G3/ MEL1S cells grew well and remained undifferentiated myeloid cells with no Mpo and Lf expression (Figures 1a-d) . At 6 days after treatment with G-CSF and TSA, the majority of the L-G3/MEL1S cells stopped growing and lost viability; the surviving cells differentiated into granulocytes and expressed Mpo and Lf. The L-G3/MEL1S cells treated with G-CSF and TSA survived 1-2 days longer than the G-CSF-treated control L-G3 cells, even though the surviving cells differentiated into mature granulocytes (Figures 1a  and c) . Therefore, TSA treatment, when combined with G-CSF, could release the blockade of granulocyte differentiation induced by MEL1S expression.
MEL1S lacking CtBP-interacting domain lost the transcriptional repressor activity
To determine the domain(s) of MEL1 that are responsible for transcriptional repression, we constructed a series of deletion mutants of MEL1S fused with the DBD of GAL4 (GAL4-DBD/MEL1) driven by the SV40 promoter. These mutants represent deletions of zinc-finger repeats 1-7 in the DBD1 (DDBD1), the proline-rich region (DPRR), the CtBP-interacting domain (CID) (DCID), the repressor domain (DRD), zinc-finger repeats 8-10 in the DBD2 (DDBD2) and the C-terminal acidic amino-acid cluster region (DCT) (Figure 2a ). Either wild-type (WT) GAL4-DBD/MEL1S or a deletion mutant plasmid was transfected along with the pG5proLuc reporter plasmid into COS-7 cells, and the protein expression of each construct was confirmed by immunoblot analysis (Figure 2b ). At 2 days after transfection, repression activity was measured by comparing the luciferase enzyme activities for each deletion construct to WT MEL1S as a reference. The repression was clearly reduced with MEL1S/DDBD1, MEL1S/ DCID or MEL1S/DRD; MEL1S/DCID showed almost no repressor activity compared with WT MEL1S. Therefore, the CID may be the most important domain for the repressor activity of MEL1S.
Amino-acid substitutions in the MEL1S CIMs block G-CSF-induced myeloid differentiation To evaluate whether the repressor activity of the CID of MEL1S is dependent on binding to the CtBP co-repressor, a MEL1S mutant carrying four amino-acid substitutions in the two CIMs (Shimahara et al., 2010) , which are located at amino-acids 588-592 (PFDLT) and 618-622 (PLDLS) (Figure 3a) , was constructed. The aspartic acid and leucine at positions 560 and 561 in the first CIM (PFDLT) were replaced by alanine and serine (PFAST), and the aspartic acid and leucine at positions 660 and 661 in the second CIM (PLDLS) were replaced by alanine and serine (PLASS) to yield the CIM mutant (CIMmt) in the GAL4-DBD/MEL1 construct. To confirm the lack of CtBP-binding ability of the MEL1/ CIMmt mutant, we transfected HA-tagged MEL1/WT, MEL1S/WT or MEL1S/CIMmt expression vectors with or without the FLAG-tagged CtBP2 expression vector into 293T cells. After immunoprecipitation using an anti-FLAG antibody, the precipitated proteins were detected using an anti-HA antibody, and CtBP2 was confirmed to bind MEL1 or MEL1S but not MEL1S/CIMmt (Figure 3b ).
Next, a study was conducted on whether the expression of MEL1S/CIMmt could block G-CSFinduced myeloid differentiation of the L-G3 cell line. After transfection of the FLAG-tagged MEL1S/CIMmt expression vector into L-G3 cells, two L-G3/CIMmt cell lines were selected by G418 treatment and established. After confirming the MEL1 expression by immunoblot analysis with an anti-FLAG antibody (Figure 3c ), the L-G3/MEL1S/CIMmt, L-G3 parental, L-G3/Mock and L-G3/MEL1S cells were treated with IL-3 or G-CSF for 6 days and their growth, cell morphology and expression of Mpo and Lf were determined. Parental L-G3 and L-G3/Mock control cells differentiated into granulocytes characterized by increased MPO and Lf mRNA levels on treatment with G-CSF, but the L-G3/MEL1S and MEL1S/CIMmt cell lines did not differentiate and remained immature myeloid cells (Figures 3d-f ). Therefore, there is probably another important element for the inhibition of differentiation, apart from the CtBP-binding sites, within the CID.
Adjacent to the CtBP-interacting consensus sequence, MEL1S is sumoylated at K568 in an UBC9-dependent manner Several transfection factors with CIM, such as ZEB1, ZEB2 and BKLF, were reported to be modified by sumoylation, facilitating the transcriptional repressor function by increasing the recruitment of HDAC. We searched for the SM cKxE (where c is a large hydrophobic residue, K is the lysine to which the SUMO is conjugated, x is any amino acid and E is glutamic acid) (Rodriguez et al., 2001) in MEL1S using the SUMOplot analysis program (ABGENT, http://www.abgent.com/ tools/sumoplot). There are seven high-probability putative SUMO consensus sites (scores over 0.69) in MEL1S (Supplementary Table 1 ). Of these, lysine 568 (AHNLL VKAE PKSPR) and lysine 85 (GLAEE LKPE GLGGG) have the highest probability of sumoylation (scores over 0.9), and lysine 568 is located just 20 amino-acid residues upstream of the CIM (PFDLT), within the CID.
To test whether MEL1S could be covalently modified by sumoylation, the FLAG-MEL1S expression vector was transfected with GFP-fused SUMO1 (GFP/ SUMO1) and the Myc-tagged conjugating enzyme UBC-9 (Myc/UBC9) or with GFP/SUMO1 and a dominant negative form of Myc/UBC-9 with cysteine 93 mutated to serine (Giorgino et al., 2000) into 293T cells. The cell lysates were subjected to sodium dodecyl sulfate (SDS)-PAGE and blotted with an anti-FLAG antibody. As shown in Figure 4a , a slowly migrating band of MEL1S was detected only in the lysates from cells transfected with SUMO1 and UBC9, but not in those expressing SUMO1 and UBC9 (C93S). To confirm whether the slowly migrating band of MEL1S corresponded to a sumoylated form of MEL1S, 293T cells were transfected under the same conditions as above, and the cell lysates were immunoprecipitated with an anti-FLAG antibody to bring down MEL1S. The precipitated proteins were then detected using an anti-FLAG or anti-GFP antibody. As shown in Figure 4b , the slower migrating band of MEL1S was detected by both antibodies, suggesting that this form of the protein likely represents a sumoylated MEL1S.
Next, to determine the location of the sumoylation site in MEL1S, six FLAG-tagged deletion mutants of MEL1S (illustrated in Figure 2a ) were transfected into 293T cells along with SUMO1 and UBC9; MEL1S protein levels were detected by immunoblotting with an anti-FLAG antibody. A sumoylated MEL1S band was detected in the lysates of cells transfected with all the MEL1S deletion mutants, except the MEL1S/ DCID mutant ( Figure 4c ). Therefore, the lysine(s) modified by sumoylation might be located within the CID. Because lysine 568 (AHNLL VKAE PKSPR), which lies within the CID, is one of the candidate lysines with a high sumoylation probability score (Supplementary Table 1 ), a MEL1S mutant was constructed with arginine substituted for lysine at position 568 (K568R; sumoylation motif mutant or SMmt) to determine whether MEL1S was sumoylated at lysine 568 ( Figure 4d ). After co-transfection with FLAG-tagged MEL1S, MEL1S/DCID, MEL1S/SMmt or MEL1S/ CIMmt and SUMO1 and UBC9, MEL1S was detected by blotting with an anti-FLAG antibody. Sumoylated MEL1S was detected in the lysates of cells transfected with MEL1/WT or MEL1S/CIMmt but not with MEL1S/DCID or MEL1S/SMmt (Figure 4e ), suggesting that lysine 568 is the sumoylated lysine within the CID. Transcriptional repression by sumoylation of MEL1S I Nishikata et al Figure 2 Transcriptional activities of MEL1S and the deletion mutants fused to the C-terminal end of the GAL4-DBD. (a) Repression activities of GAL4-DBD-fused MEL1S and its deletion mutants. COS-7 cells were co-transfected with the pGL3-promoter vector control (pGL3-p) or pG5proLuc with five consensus GAL4-binding sites (UAS) and the internal control plasmid pRL-MP together with the mock expression vector (GAL4-DBD), GAL4-DBD/MEL1S or the deletion mutants, as illustrated in Figure 2a . After 48 h of incubation, the cell extracts were prepared, and reporter activity was determined according to the manufacturer's instructions. Values of relative luciferase activity represent the mean±s.d. of three independent transfections. *Po0.05 (Student's t-test). (b) The protein expression levels of transfected MEL1S and the deletion mutants in COS-7 cells were determined by immunoblotting using the anti-GAL4-DBD antibody. The expression of GAL4-DBD/MEL1S fusion proteins (top panel) and Mock constructs (middle panel) were analyzed by 5 and 15% SDS-PAGE, respectively. b-Actin was used as an internal control. Molecular weight markers are given in kilodaltons (kDa). Stars indicate nonspecific bands. Figure 3 Forced expression of the MEL1S mutant harboring disrupted CIM blocks G-CSF-induced granulocytic differentiation. (a) Schematic illustration of human MEL1S and the mutant form of MEL1S. PRD indicates the PR domain; DBD1, DNA-binding domain 1; PRR, the proline-rich region; CID, the CtBP-interacting domain; RD, the repression domain; DBD2, DNA-binding domain 2; and AD, the acidic domain. MEL1S has two CIMs (PFDLT and PLDLS). The motifs reside in the CID of MEL1S. The two CIMs, PFDLT and PLDLS, were mutated to PFAST and PLASS, respectively, by site-directed mutagenesis. (b) MEL1S interacts with CtBP2 through the CIM. HA-tagged MEL1, MEL1S or MEL1S/CIM mutant was transiently expressed with FLAG-tagged CtBP2 in 293T cells. HA-tagged MEL1 proteins and FLAG-CtBP2 were immunoprecipitated using an anti-HA antibody and an anti-FLAG antibody, respectively. The precipitated proteins were separated by SDS-PAGE and MEL1, MEL1S, the CIM mutant and/or CtBP2 were detected by western blotting (top panels). The inputs of each assay are shown on the bottom panels. (c) Expression of MEL1S (FLAG/MEL1S/WT) and the mutant (FLAG/MEL1S/CIMmt and FLAG/MEL1S/SMmt/CIMmt) clones in retrovirally infected L-G3 cell lines. Cell extracts from L-G3 cells infected with retrovirus containing FLAG-tagged MEL1S or its mutants were subjected to immunoblotting using the anti-FLAG antibody. Expression of b-Actin, which served as an internal control, is shown in the lower panel. Molecular weight markers are given in kDa. (d) Growth curves of L-G3 cells infected with retrovirus encoding a MEL1S mutant harboring disrupted CIM. L-G3 cells stably expressing either FLAG-tagged MEL1S (L-G3/MEL1S), the CtBP interaction mutant (L-G3/MEL1S/CIMmt, #1 and #2, which correspond to lanes 5 and 6 in Figure 3c (Figure 5a ). The repressive activity of MEL1S/SMmt was slightly reduced compared with that of MEL1S/WT, and the activity of MEL1S/CIMmt was moderately reduced. Interestingly, the repression activity of MEL1S/SM/CIMmt was negligible, suggesting that both the sumoylation and the CtBP-binding property might contribute to the transcriptional repressor activity of MEL1S.
HDAC interacts with the sumoylated and CtBP-interacting regions in the CID of MEL1S Because transcriptional repression by MEL1S may involve the recruitment of HDAC, the binding of HDAC to the SM and CIMs was assessed in the CID of MEL1S as EVI1 (Mitani, 2004; Maki et al., 2008) . For this experiment, the expression vectors were constructed containing a GFP-fused CID (GFP/CID) containing various mutations, such as CID/SMmt, CID/CIMmt or CID/SM/CIMmt (Figure 6a) , which contain the same amino-acid substitutions as in Figures  3a and 4d . These constructs were transfected with or without a FLAG-tagged HDAC2 expression vector into 293T cells, and the cell lysates were immunoprecipitated with an anti-FLAG M2 affinity gel. The precipitated proteins were detected using an anti-GFP antibody. The precipitated GFP/CID protein was clearly detected in the lysates of cells transfected with GFP/CID/WT, but the level of the GFP/CID protein was clearly decreased with the GFP/CID/SMmt and GFP/CID/CIMmt expression vectors (Figure 6b) . Moreover, the GFP/CID/SM/ CIMmt protein was not co-immunoprecipitated with FLAG-HDAC2, suggesting that HDAC failed to interact with GFP/CID/SM/CIMmt. Therefore, HDAC could bind to both the SM and the CIM in the CID. MEL1S was sumoylated at lysine 568 in a SM adjacent to the CIM. (a) Sumoylation of MEL1S is dependent on UBC9. Cells (293T) were co-transfected with expression plasmids encoding FLAG/MEL1S, Myc-tagged UBC9 or Myc-tagged dominant negative UBC9 (the C93S mutant) and/or GFP/SUMO1. The cell lysates were analyzed by western blotting using an anti-FLAG antibody. Expression of UBC9, SUMO1 and b-Actin is shown in the three lower panels. Molecular weight markers are given in kDa.
(b) Identification of sumoylated MEL1S by immunoblot analysis. Flag-tagged MEL1S with Myc/UBC9 was transfected along with control GFP or GFP-fused SUMO1 into 293T cells. After immunoprecipitation with an anti-FLAG antibody, sumoylated MEL1S was detected using an anti-GFP antibody for GFP/SUMO1 in the left panel. In the right panel, after immunoprecipitation out of the same samples with the anti-FLAG antibody, MEL1S was identified using an anti-FLAG antibody. (c) The detection of the more slowly migrating band of MEL1S as a sumoylated form of MEL1S by transfection of expression vectors containing each MEL1S mutant is indicated in Figure 2a , with or without Myc/UBC9 and GFP/SUMO1 expression plasmids. Cells (293T) were transfected under the same conditions as in Figure 4a , and the cell lysates were analyzed by western blotting using an anti-FLAG antibody.
Molecular weight markers are given in kDa. Stars indicate sumoylated MEL1S. (d) Schematic illustration of human MEL1S and the mutant form of MEL1S. MEL1S has a SM (VKAE) adjacent to two CIMs (PFDLT and PLDLS)
. These motifs are located in the CID of MEL1S. The SM was mutated to VRAE by site-directed mutagenesis. Abbreviations are the same as in Figure 3a . (e) The MEL1S K568R mutant cannot be sumoylated. An expression plasmid encoding either FLAG/MEL1S (WT), the CID-deleted MEL1S mutant (DCID), the SM-abolished mutant (SMmt) or the CIM-abolished mutant (CIMmt) was transfected with or without Myc/UBC9 and GFP/SUMO1 expression plasmids into 293T cells, and the cell lysates were analyzed by western blotting using an anti-FLAG antibody. Expression of UBC9, SUMO1 and b-Actin is shown in the three lower panels. Figures 2a, b, c, d and e). To confirm whether MEL1S was sumoylated in L-G3 cells, stable -L-G3 cell lines expressing WT or mutant MEL1S were transfected with Myc/UBC9 and GFP/SUMO1 expression plasmids, and sumoylation levels were determined by western blot analysis with the anti-FLAG antibody. A slowly migrating band corresponded to sumoylated MEL1S and was detected in the lysates from MEL1S/WT and MEL1S/CIM cells but not from MEL1S/SM/CIMmt #1 or #2 cells (Figure 7e ). These data suggest that the ability of MEL1S to block differentiation was primarily dependent on the transcriptional repression activity mediated by both sumoylation and CtBP binding in the CID of MEL1S.
Discussion
In this study, we showed that sumoylation of and CtBP interaction with the CID cooperatively mediated transcriptional repression activity of the MEL1 zincfinger protein; in addition, MEL1 transcriptional repression activity was found to be essential for its blockade of G-CSF-induced granulocyte differentiation of Transcriptional repression by sumoylation of MEL1S I Nishikata et al murine IL-3-dependent L-G3 cells. We have identified an important SUMO acceptor site at lysine 568, which lies just adjacent to the CIM, within the CID. Aminoacid substitutions in the SM and CIM of MEL1S completely abrogated the protein's transcriptional repression activity and its recruitment of the HDAC complex. Finally, L-G3 cells were stably transfected with a double mutant of MEL1S (SM/CIMmt) and differentiated into granulocytes on treatment with G-CSF. Although the sumoylation status of MEL1S has not been shown in acute myeloid leukemia cells, these data demonstrate that the overexpression of MEL1 in a myeloid cell line could inhibit G-CSFinduced granulocyte differentiation through transcriptional repression of yet unidentified genes, and this pathway may contribute to myeloid leukemogenesis. Several C 2 H 2 zinc-finger transcription factors contain CIM and SM that have an important role in modulating transcriptional repressor activity. BKLF, a Kru¨ppel-like C 2 H 2 zinc-finger transcription factor expressed in erythroid cells, contains a CIM and two SMs (Perdomo et al., 2005) . The SUMO site at K10 resides in the repression domain and is located 41 amino-acids upstream from the CIM, and the other SUMO site (K198) is located between the repressor domain and the zinc-finger DBD (Perdomo et al., 2005) . Sumoylation and interaction with CtBP synergistically enhanced the transcriptional repression activity of BKLF (Perdomo et al., 2005) . Both ZEB1 and ZEB2 have been reported to be sumoylated on two conserved lysine residues; one SUMO site (K774 in ZEB1 and K866 in ZEB2) is located adjacent to a CIM, and another site (K347 in ZEB1 and K391 in ZEB2) is located between the first zinc-finger cluster (composed of zinc-finger repeats 1-4) and the Smad-binding domain. Mutations of these two sumoylated lysine residues in ZEB1 caused a loss of the transcriptional repression function of ZEB1, and the DNA binding ability of ZEB1 was shown to be dependent on the sumoylation of the two lysine residues in a chromatin immunoprecipitation assay (Kuppuswamy et al., 2008) . Conversely, the sumoylation of ZEB2 attenuates its transcriptional repression of E-cadherin, which is caused by reduced binding to the co-repressor CtBP (Long et al., 2005) . Although the function of sumoylation of zinc-finger transcription factors with CIM differs from one transcription factor to the next, sumoylation of the BKLF and MEL1S transcription factors may facilitate recruitment of the HDAC complex to increase transcriptional repression activity; however, a study of BKLF did not show an increased recruitment of the HDAC complex upon sumoylation (Perdomo et al., 2005) .
Hematopoietic cell differentiation is regulated by lineage-specific transcription factors that function in a mutually antagonistic manner. For example, MafB and c-Myb function as antagonists for each other in a balance between macrophage differentiation and myeloid progenitor expansion. C-Myb suppresses MafB-driven differentiation through sumoylation of MafB (Tillmanns et al., 2007) ; conversely, c-Myb is also affected by sumoylation. TRAF7, a SUMO ligase, sequesters c-Myb in the cytoplasm by increasing its sumoylation (Morita et al., 2005) . Thus, sumoylation is one of the important regulatory events in cellular differentiation and proliferation. Interestingly, MEL1/ PRDM16 is one of transcription factors in the regulation of brown fat versus white fat/skeletal muscle differentiation . In myoblasts and preadipocytes, MEL1/PRDM16 promotes the expression of brown fat cell-selective genes by co-activating the transcriptional activity of PGC-1a/1b and PPARa/g through direct interaction . In addition, MEL1/PRDM16 represses the expression of white fat-or skeletal muscle-specific genes by association with the co-repressor CtBP (Kajimura et al., 2009) . Although the mechanisms underlying the molecular switch that changes MEL1/PRDM16 from a transcriptional activator to a repressor have not yet been elucidated, sumoylation may have an important role in this transcriptional switch. Given that the overexpression of MEL1S was found to block the granulocytic Figure 3a. (b) Neither the SM nor the CIM-disrupted CID can interact with HDAC2. Either a GFP/CID fusion (WT, SMmt, CIMmt, SM/CIMmt) vector or the mock (GFP) vector was co-transfected with or without a vector expressing FLAG/HDAC2 into 293T cells. The cell lysates were subjected to immunoprecipitation with the anti-FLAG antibody and blotted with an anti-GFP antibody. WT GFP/CID and the three mutant forms that interacted with HDAC2 are shown in the top panel. The direct western blotting of CID using the anti-GFP antibody and of HDAC2 using the anti-FLAG antibody are shown in the middle and bottom panels, respectively. differentiation of L-G3 myeloid leukemia cells, inhibition of MEL1S sumoylation through targeting of tissuespecific SUMO ligases may present a novel strategy in myeloid leukemia. The SUMO ligases for MEL1S in hematopoietic stem cells and/or myeloid progenitor cells remain to be identified. 
Materials and methods

Plasmid constructions
To construct human MEL1S expression vectors, a FLAG-or a hemagglutinin (HA)-epitope tagged, short-form MEL1 lacking an N-terminal PR domain (MEL1S) (Mochizuki et al., 2000; Nishikata et al., 2003) was placed under the control of a cytomegalovirus (CMV) promoter in a mammalian expression vector pCMV26 (Sigma-Aldrich, St Louis, MO, USA) (pFLAG-MEL1S or pHA-MEL1S). To construct the human MEL1 expression vector, a HA-epitope tagged, long-form MEL1 with a PR domain (Mochizuki et al., 2000; Nishikata et al., 2003) was inserted into the pCMV26 (pHA-MEL1). Using the In-Fusion cloning kit (Clontech, Mountain View, CA, USA), deletion mutants of MEL1S, including MEL1S/DDBD1 (DBD1, containing the 1-7 zinc-finger repeats, aa 40-264), MEL1S/DPRR (proline-rich region, aa 265-522), MEL1S/DCID (CID, aa 523-644), MEL1S/DRD (repression domain, aa 645-766), MEL1S/DDBD2 (DBD2, containing the 8-10 zinc-finger repeats, aa 767-887) and MEL1S/DCT (C-terminal region containing acidic domain, aa 893-1072), were generated by PCR amplification of human MEL1S complementary DNA lacking each domain structure (Figure 2a) . To generate MEL1S mutants with amino-acid substitutions, a mutant with lysine 568 replaced by arginine in the SM (MEL1S/SMmt with K568R), the CIM mutant MEL1S-CIMmt (PFAST at aa 588-592 and PLASS at aa 618-622), and the double mutant (MEL1S/SM/CIMmt) were generated using a Quick Change II site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The GAL4 DBD-fused MEL1S expression constructs with various deletions and amino acid replacements were cloned into the pM expression vector (Clontech). The murine CtBP2 expression vector, pFLAG-CtBP2, contained a full-length murine CtBP2 (kindly provided by Dr Crossley; Turner and Crossley, 1998) cloned into the FLAG-epitope tag expression vector pFLAG-Mock. The human UBC9 expression vectors, pMyc-UBC9 and pMyc-UBC9DN, contain full-length human UBC9 and the dominant negative mutant (C93S), respectively, cloned into the Myc-epitope tag expression vector pMyc-Mock. The human SUMO expression vector pGFP-SUMO1 contains full-length human SUMO-1 and was cloned into the pGFP-epitope tag expression vector pGFP-Mock. A series of CID fragments from MEL1S containing WT CID (CID/WT) or CID with a series of amino-acid substitutions (CID/SMmt, CID/CIMmt and CID/SM/CIMmt) were cloned into the pGFP-epitope tag expression vector pGFP-Mock. The chicken HDAC2 expression vector pFLAG-HDAC2 and the Mock vector were kindly provided by Dr Y Takami (University of Miyazaki, Miyazaki, Japan). For the reporter gene assay, the pG5proLuc vector was used as a reporter expressing firefly luciferase (Nishikata et al., 2003) . The TK promoter in the pG4.74 Renilla luciferase internal control vector (Promega, Madison, WI, USA) was replaced with the minimum promoter (MP) from the pGL4.23 firefly luciferase reporter vector (Promega) to generate pRL-MP.
Mammalian cell culture, transfection and infection
Human embryonic kidney 293T (DuBridge et al., 1987) , BOSC23 (Pear et al., 1993) and simian kidney COS-7 cells (Gluzman, 1981) were maintained in Dulbecco's modified Eagle's medium (DMEM, Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS, Biofluids, Camarillo, CA, USA). IL-3-dependent murine myeloid cell lines, L-G3 (Kinashi et al., 1991) and 32Dcl3 (Greenberger et al., 1983; Migliaccio et al., 1989) were maintained in RPMI 1640 (Wako) with 10% FBS and 5 ng/ml murine IL-3 (mIL-3, Kirin Brewery Co., Tokyo, Japan). The cells were grown in 5% CO 2 at 37 1C. Transfections were carried out using the Hilymax transfection reagent (DOJINDO, Kumamoto, Japan), according to the manufacturer's instructions. Transfection studies of L-G3 transformants for sumoylation assays and of 32Dcl3 cells for the generation of stable transformants were carried out using the Amaxa Nucleofection systems (Wako), according to the manufacturer's instructions. Cells were harvested 48 h after transfection for further analysis.
Retroviral infections
To generate L-G3 clones stably expressing WT human MEL1S and two of its mutants (MEL1S/CIMmt and MEL1S/SM/ CIMmt), the respective complementary DNA sequences Transcriptional repression by sumoylation of MEL1S I Nishikata et al were subcloned into the retroviral vector pLXSN (Clontech). Infectious retroviral particles bearing FLAG-tagged MEL1S/ WT, MEL1S/CIMmt, or MEL1S/SM/CIMmt were prepared by transfection of the virus-producing BOSC23 cells with each retroviral expression vector. Neomycin-resistant clones were screened for expression of the FLAG-tagged proteins by immunoblot analysis using an anti-FLAG rabbit polyclonal antibody (Sigma-Aldrich).
Proliferation and differentiation assays
The L-G3 or 32Dcl3 stable cell lines were seeded at 1 Â 10 5 cells/well in a 6-well dish and incubated for 24 h. The cells were subsequently washed twice in RPMI 1640 and incubated with 5 ng/ml mIL-3, 5 ng/ml G-CSF, 5 ng/ml G-CSF and 3 ng/ml TSA (Wako) or no growth factor for 6 (L-G3) or 9 days (32Dcl3). The morphological observations were studied by cytospinning the cells onto glass slides and staining with MayGru¨nwald-Giemsa solution (Merck, Darmstadt, Germany). For the measurement of viable cell numbers, live cells were counted at indicated intervals using trypan blue exclusion (Sigma-Aldrich). Murine IL-3 and G-CSF were kindly provided by Kirin Brewery Co. All results were reproduced twice.
Immunoprecipitation and immunoblot analyses
Transfected cells were directly lysed in SDS sample buffer, boiled, resolved on 5 or 10% SDS-polyacrylamide gels, and transferred to polyvinylidene fluoride (PVDF) membranes (Immobilon-P, Millipore, Billerica, MA, USA). For immunoprecipitation assays, 5 Â 10 6 cells were washed in phosphatebuffered saline and solubilized with 450 ml of radioimmune precipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1% Triton X-100), which was supplemented with a protease inhibitor cocktail (SigmaAldrich). After centrifugation, the supernatants were incubated with 50 ml of anti-Flag M2 affinity gel (Sigma-Aldrich) overnight with rotation at 4 1C. The resins were washed three times with RIPA buffer, and proteins were eluted in SDS sample buffer. The detection of FLAG-, HA-, Myc-and GFPtagged proteins was carried out using rabbit anti-Flag (1:1000, Sigma-Aldrich), rat monoclonal anti-HA (1:1000, 3F10, Roche, Manheim, Germany), mouse monoclonal anti-Myc (1:1000, 9B11, Cell Signaling Technology, Danvers, MA, USA) and rabbit anti-GFP (1:1000, MBL, Nagoya, Japan) antibodies. Mouse monoclonal anti-GAL4 DNA-BD (1:2000, Clontech), rabbit anti-MEL1 DBD1 (1-7 zinc-finger cluster) and DBD2 (8-10 zinc-finger cluster, 1:1000) antibodies (Nishikata et al., 2003) were also used, and a mouse monoclonal anti-b-Actin antibody (1:5000, AC15, Sigma-Aldrich) was used to provide an internal loading control. Horseradish peroxidaselinked swine anti-rabbit, rabbit anti-rat (DakoCytomation Denmark A/S, Glostrup, Denmark), and sheep anti-mouse (GE Healthcare, Little Chalfont, England) immunoglobulins were used as secondary antibodies. Immunoreactive proteins were visualized on LAS-3000 (Fuji-film, Tokyo, Japan) using a Lumi-Light Plus western blotting substrate (Roche). All results were reproduced twice.
Reverse-transcriptase-PCR Total RNA was extracted from each cell using Trizol reagents (Invitrogen, Carlsbad, CA, USA) and converted to complementary DNA using AMV reverse transcriptase (Takara, Shiga, Japan). The complementary DNA was used as a template for PCR performed by ExTaq polymerase (Takara), and the primers used were as follows: for mouse Mpo, forward 5 0 -CGCTTCTCCTTCTTCACTGG-3 0 and reverse 5 0 -CTGCC ATTGTCTTGGAATCG-3 0 ; for mouse Lf, forward 5 0 -AAAC AAGCATCGGGATTCCAG-3 0 and reverse 5 0 -ACAATGC AGTCTTCCGTGGTG-3 0 ; and for mouse b-Actin, forward 5 0 -TTCCTTCTTGGGTATGGAAT-3 0 and reverse 5 0 -GAGC AATGATCTTGATCTTC-3 0 .
Reporter gene assay
Reporter gene assays were carried out using a GAL4-responsive artificial promoter-luciferase plasmid (pG5proLuc) (Nishikata et al., 2003) . Briefly, COS-7 cells were transfected in 12-well plates with 2 mg of DNA, which included the indicated reporter constructs and expression vectors, as well as 100 ng of pRL-MP plasmid as an indicator of transfection efficiency. The luciferase activities (firefly luciferase for the reporter and Renilla luciferase for the indicator) were measured using the Dual-Luciferase Assay System (Promega). All transfections were carried out in triplicate. The data obtained were compared with the control and statistically analyzed by Student's t-test.
